DiabetesIndia 2022: What Future Treatments are on the Horizon for NAFLD?


Dr Shalini Jaggi, New Delhi    16 December 2022

  • One in five individuals globally are estimated to have nonalcoholic fatty liver disease (NAFLD).
  • Its prevalence is strongly associated with obesity and metabolic disorders; however, evidence is mounting occurrence among nonobese individuals.
  • Whilst bland steatosis itself is not harmful, it lays the foundation for the development of nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC).
  • The complex and heterogeneous nature of NAFLD challenges the quest to find the holy grail of treatments.
  • So far treatments are generally aimed at directly ameliorating either one of the hallmark characteristics driving NAFLD (steatosis, inflammation and fibrosis) or the gut microbiome.
  • The NAFLD treatment landscape is rapidly evolving as a consequence of our growing understanding of its underpinning mechanisms.
  • Treatments aimed at ameliorating not one, but multiple, features of the condition hold great promise.
  • Several treatments have been tested in clinical trials, and whilst some promising results have been obtained, most have failed to deliver the desired outcome.
  • Increasing appreciation of the heterogeneity of NAFLD will enable us to develop more personalized therapies. Whilst the holy grail has not yet been found; step by step, its quest is ongoing and getting closer to the discovery of successful NAFLD treatments.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.